Mapping AMR research funding, research centres and infrastructures
JPIAMR previously mapped funded scientific research in the area of antimicrobial resistance from 2007-2013. In 2017, JPIAMR initiated a similar but more extensive mapping exercise on AMR related to projects and funding, research centres/units, research infrastructures, and industry alliances. The aim of this mapping is to enable researchers, funders and industries to (1) determine what has already been funded across the different areas of AMR research, (2) avoid duplication and identify potential partnering opportunities, and (3) determine what is still required in order to set strategic priorities.
Mapping of AMR Research Funding (2014)
In 2014, the JPIAMR conducted the first systematic analyses of public funding of research on antibacterial resistance. Databases of public funding organisations across 19 countries, and at EU level, were systematically searched for publicly funded antibacterial resistance research from 2007 to 2014, and categorised around the JPIAMR strategic research agenda’s six priority topics (therapeutics, diagnostics, surveillance, transmission, environment, and interventions).
We identified 1243 antibacterial resistance research projects, with a total public investment of €1.3 billion across 19 countries and at the EU level, including public investment in the Innovative Medicines Initiative. Of the total amount €646.6 million (49.5%) was funded at the national level and €659.2 million (50.5%) funded at the EU level. Most of the funded projects focused on the therapeutics area, of which 763 (63%) of 1208 projects at national level were funded within this area, versus 185 (15%) in transmission, or only 37 (3%) in environment.
The picture of this funding landscape guided the JPIAMR member countries and their joint investments towards future AMR research. The study highlighted the need for increased investment across all member countries and also to diversify investments beyond the therapeutics area.
Mapping of AMR research funding (2018)
The aim of the 2018 mapping exercise is to obtain an overview of the grant investments, research capacity and scope among JPIAMR member countries for AMR research. This involves mapping of antimicrobial resistance (including anti-fungal, anti-parasitic and anti-bacterial) research undertaken in the 27 member countries and research funded by the European Commission. Project data relevant to antimicrobial resistance, within the broad remit of the six priority topics identified in the JPIAMR Strategic Research Agenda (SRA) will be included in the mapping exercise. This mapping will provide an objective insight into the scale and scope of publicly funded AMR research and associated investment in the JPIAMR member countries. The aim is to identify gaps and prioritisation of specific research areas identified in the SRA to determine future investments.
Data collection and inclusion criteria:
- Data on AMR research project funding from JPIAMR joint calls and national funding agencies of the JPIAMR member countries to monitor investments in projects ranging from basic, applied and clinical research, and epidemiological, public health, veterinary and environmental research related to AMR issues, including clinical trials.
- Grant investments by different organisations of JPIAMR member countries for awards and resources that are live (active) or where funding has been committed from the 1st January 2017.
- Research relevant to AMR along with basic bacteriology and infectious disease with the potentiality to contribute to the overall AMR research effort in the long term.
- Information on grant investments in relation to bacterial, fungal and parasitic resistance.
21 member countries, as well as the European Commission, have participated in the 2018 mapping exercise. An overview of the analyses of the mapped data will soon be available.
Each JPIAMR member country will also provide data and information relevant for the following mapping activities:
Mapping of AMR research centres/units
AMR research is also carried out at specific research centres/units where (not all) funding is through competitive project grants. This mapping is focused on institutional funding. We will collect data regarding research centres that have significant contributions to AMR research. A dynamic network of AMR research units will provide a close contact between the JPIAMR and the scientific community and will help to build research capacity in the area of AMR. It will aim to contribute to the establishment of a Virtual Research Institute.
Mapping of AMR Research infrastructures
Limited sharing and linkage of samples, strains and data is a key barrier for AMR research. Financial and scientific investments have been committed in several member states and thousands of citizens have voluntarily contributed data and bio-specimens to biobanks and databases. Mapping of the existing AMR research infrastructure within the member states will better coordinate the databases and biobanks and will ensure effective interchange of valid information and samples. Research infrastructure mapping under the JPIAMR banner aims to harmonise resources and enhance coordination of research efforts that could be used for translational research, clinical care, personalised medicine and maximise public health benefits.
Mapping of AMR Industry alliances
Mapping of industries working in the AMR field and their specific needs will be conducted to improve data sharing and communication between academia and industry.
The recent WHO review shows that the current clinical pipeline is still insufficient to mitigate the threat of antimicrobial resistance. JPIAMR has contributed to the WHO antibiotic development pipeline analyses through reviewing pipeline data and advising on the method for analyses. JPIAMR is continuing its efforts to find solutions to the challenges presented by WHO by processing current and future calls that fund research on the very challenges highlighted in the report. The full report is available here.
JPIAMR also has a specific industrial focus. It aims to address the need of developing new antibiotics by supporting small and medium-sized enterprises (SMEs). This will be realised by establishing collaboration with the BEAM (Biotech companies in Europe combating Antimicrobial Resistance) Alliance who are committed to engaging European small and medium biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.